同步放化疗联合免疫治疗对晚期恶性黑色素瘤患者生存率的影响

Influences of Concurrent Chemoradiotherapy and Immunotherapy on Survival Rate of Patients with Advanced Malignant Melanoma Tumors

目的:探讨同步放化疗联合免疫治疗对延长晚期恶性黑色素瘤患者生存率的临床效果。方法:79例晚期恶性黑色素瘤患者,按随机数字表随机分成同步放化疗联合免疫治疗组(试验组)40例,单纯同步放化疗组(对照组)39例。观察两组患者不良反应、3个月、6个月、12个月、24个月生存率及总中位生存期。结果:两组治疗后试验组不良反应明显比对照组少(P<0.05)。两组24个月生存率比较有统计学差异(P<0.05),总中位生存期(P<0.01)。结论:同步放化疗联合免疫治疗能减少患者治疗后的不良反应发生,延长晚期恶性黑色素瘤患者的生存期,是目前晚期恶性黑色素瘤患者比较理想的治疗方法。

Objective： To investigate the clinical effect of concurrent chemoradiotherapy and immunotherapy to prolong the survival rate of patients with advanced malignant melanoma tumor. Methods： 79 patients with advanced malignant melanoma were randomly divided into 40 cases in immunotherapy and concurrent chemoradiotherapy group（ experimental group）,39 cases in concurrent chemoradiotherapy alone（ control group）. Adverse reactions,3-month,6-month,12-month and 24-month l survival rate,and median survival time were observed in two groups. Results： After treatment,adverse reactions in the experimental group were significantly less than the control group（ P〈 0. 05）. 24-month survival rates and median overall survival in two groups were statistically significant（ P〈 0. 03,P〈 0. 01）. Conclusion： The chemoradiotherapy combined with immunotherapy can reduce adverse reactions and prolong survival time,which is an ideal method for patients with advanced malignant melanoma after treatment.